Long-term survival of patients with primary oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study

被引:0
作者
Kessler, Peter
Grabenbauer, Gerhard
Leher, Anna
Bloch-Birkholz, Alexandra
Vairaktaris, Elephtherios
Neukam, Friedrich Wilhelm
Sauer, Rolf
机构
[1] Univ Erlangen Nurnberg, Klin & Poliklin Mund Kiefer & Gesichtschirurg, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Klin & Poliklin Strahlentherapie, D-91054 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Inst Med Informat Biometrie & Epidemiol, D-91054 Erlangen, Germany
[4] Univ Athens, Sch Med, Dept Maxillofacial Surg, GR-11527 Athens, Greece
关键词
oral squamous cell carcinoma; tumor therapy; survival;
D O I
10.1007/s00066-007-1469-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose: In recent years, different concepts for the treatment of oral squamous cell carcinomas (OSCC) have been developed; these include preoperative simultaneous neoadjuvant radiochemotherapy and one-stage surgery with tumor ablation and reconstruction. When considering long-term survival, there is substantial evidence that multimodality treatment based on a neoadjuvant radiochemotherapy is superior to adjuvant therapy concepts based on a surgical approach with postoperative irradiation. The aim of this study was to discuss the 5-year survival rate in a neoadjuvant and an adjuvant combination treatment in patients with primary OSCC. Patients and Methods: This nonrandomized longitudinal study prospectively evaluates the long-term tumor-free survival in 128 patients with oral cancer. Two groups consisting of 74 neoadjuvantly and 54 primarily surgically treated patients were formed. 99 patients suffered from stage III and IV disease according to the UICC criteria. Long-term survival was estimated according to the Kaplan-Meier assumption. Results: The neoadjuvant treatment increases the prospect of a long-term tumor-free survival. According to Kaplan-Meier assumption the estimation for a 5-year tumor-free survival in OSCC in category T1 is 83.1% in neoadjuvant, and 70.1% in adjuvant treatment, in T2 79.6% and 57.7%, in T3 68.2% and 33.2%, in T4 51.4% and 30.5%, respectively. Significance (p < 0.05) could be proven for T1 (p = 0.002), T2 (p = 0.028), and T4 (p < 0.0001) tumors. The effectiveness of the preoperative radiochemotherapy was demonstrated in the pathohistological result of tumor-free resection specimens in 28 patients of the neoadjuvant treatment group (37.8%). On the other hand, four patients died during the preoperative combination therapy. 64.8% of the patients in the adjuvant and 71.6% in the neoadjuvant treatment group survived the observation period. Conclusion: Neoadjuvant therapy is highly effective and results in a better 5-year survival rate than adjuvant treatment. All patients with primary OSCC should be selected for such a treatment. Future therapy concepts should combine the effectiveness of a systemic treatment with the safety of a limited surgical resection of the tumor site to preserve as much function as possible.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 48 条
[1]  
Adelstein DJ, 2000, CANCER, V88, P876, DOI 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO
[2]  
2-Y
[3]   Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology [J].
Bernier, J ;
Bentzen, SM .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (05) :560-571
[4]  
BUDACH VG, 2003, INT J RAD ONCOL BI S, V57, P153
[5]   Management of the clinically positive neck in organ preservation for advanced head and neck cancer [J].
Dagum, P ;
Pinto, HA ;
Newman, JP ;
Higgins, JP ;
Terris, DJ ;
Goffinet, DR ;
Fee, WE .
AMERICAN JOURNAL OF SURGERY, 1998, 176 (05) :448-452
[6]   Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma [J].
Denis, F ;
Garaud, P ;
Bardet, E ;
Alfonsi, M ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Calais, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :69-76
[7]  
Ernst-Stecken A, 2004, STRAHLENTHER ONKOL, V180, P805, DOI 10.1007/s00066-004-1307-1
[8]  
FIETKAU R, 1991, Strahlentherapie und Onkologie, V167, P693
[9]   Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma - A Hellenic Cooperative Oncology Group Phase II Study [J].
Fountzilas, G ;
Tolis, C ;
Kalogera-Fountzila, A ;
Karanikiotis, C ;
Bai, M ;
Misailidou, D ;
Samantas, E ;
Athanassiou, E ;
Papamichael, D ;
Tsekeris, P ;
Catodritis, N ;
Nicolaou, A ;
Plataniotis, G ;
Makatsoris, T ;
Papakostas, P ;
Zamboglou, N ;
Daniilidis, J .
STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (04) :223-230
[10]   LATE EFFECTS OF HYPERFRACTIONATED RADIOTHERAPY FOR ADVANCED HEAD AND NECK-CANCER - LONG-TERM FOLLOW-UP RESULTS OF RTOG-83-13 [J].
FU, KK ;
PAJAK, TF ;
MARCIAL, VA ;
ORTIZ, HG ;
ROTMAN, M ;
ASBELL, SO ;
COIA, LR ;
VORA, NL ;
BYHARDT, R ;
RUBIN, P ;
SORGEN, SD ;
COX, JD ;
STETZ, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (03) :577-588